<DOC>
	<DOCNO>NCT00996333</DOCNO>
	<brief_summary>This study design determine whether investigational drug combination consist Gemzar® , Taxotere® , Xeloda® , ( call GTX ) safe effective treating advance pancreatic cancer study enhance utility PET scan evaluation patient pancreatic cancer .</brief_summary>
	<brief_title>Study Gemzar® , Taxotere® , Xeloda® ( GTX ) Patients With Metastatic Pancreatic Cancer ( Stage IVB )</brief_title>
	<detailed_description>This Phase II multicenter study design determine response rate biochemically synergistic regimen Gemzar , Taxotere , Xeloda patient Stage IVB metastatic pancreatic cancer . It determine overall one year survival rate , diseasefree interval , toxicity regimen patient metastatic pancreatic cancer .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm adenocarcinoma pancreas metastatic liver and/or lung peritoneal surface . ( a.k.a . Stage IV B ) . No prior chemotherapy Gemzar , Xeloda Taxotere . Measurable disease : Any mass reproducibly measurable two perpendicular diameter xray , physical examination , CT MRI scan . The following lesion conventionally consider measurable : CNS lesion Blastic lytic bone lesion ( document follow ) Radiated lesion unless progression RT document Ineligible high priority national institutional study Prior radiation surgery allow : &gt; 3 week since surgery &gt; 4 week since RT Non pregnant female breast feed negative serum urine βHCG test within 1 week start study . Men woman childbearing potential must willing consent use effective contraception treatment reasonable period thereafter . Clinical Parameters : Life expectancy &gt; 2 month Age 18 70 year old Performance status 02 ( ECOG ) Peripheral Neuropathy must &lt; grade 1 Able tolerate oral medication Required initial laboratory data : Absolute Neutrophil Count &gt; 1,500 μl White Blood Count &gt; 3,000/μl Platelet count &gt; 100,000/μl BUN &lt; 1.5 x normal Creatinine &lt; 1.5 normal Hemoglobin &gt; 8.0 g/dl Serum Albumin &gt; 3 mg/dl Total Bilirubin &lt; 2.0 mg/dl SGOT , SGPT , Alkaline Phosphatase SGOT SGPT may 3.0 x ULN Alk Phos &lt; 2.0 x ULN ; Alk Phos may 3.0 x ULN SGOT SGPT &lt; 2.0 x ULN Hypersensitivity : Patients history severe hypersensitivity reaction Taxotere® drug formulate polysorbate 80 must exclude . Informed Consent : Each patient must completely aware nature his/her disease process must willingly give consent inform experimental nature therapy , alternative , potential benefit , sideeffects , risk , discomfort . The patient prior malignancy last 5 year curatively treat carcinoma insitu cervix nonmelanoma skin cancer No serious medical psychiatric illness prevent informed consent intensive treatment ( e.g. , serious infection ) . Patients brain metastasis exclude . Patients know HIV exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Stage IVB</keyword>
</DOC>